Oxford Biomedica’s (OXB) “Outperform” Rating Reaffirmed at Royal Bank Of Canada

Royal Bank Of Canada restated their outperform rating on shares of Oxford Biomedica (LON:OXB) in a research note issued to investors on Tuesday morning,Digital Look reports. Royal Bank Of Canada currently has a GBX 900 price objective on the biopharmaceutical company’s stock.

Several other equities research analysts also recently commented on OXB. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 8.27 price objective on shares of Oxford Biomedica in a report on Tuesday, June 2nd. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a GBX 595 target price on shares of Oxford Biomedica in a research note on Wednesday. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of GBX 580.85.

Oxford Biomedica Stock Down 2.9%

OXB stock opened at GBX 434 on Tuesday. The stock has a market capitalization of £525.30 million, a P/E ratio of -16.12 and a beta of 1.10. The company has a debt-to-equity ratio of 162.16, a current ratio of 2.20 and a quick ratio of 1.67. Oxford Biomedica has a 1-year low of GBX 427 and a 1-year high of GBX 952. The business has a fifty day moving average price of GBX 566.92 and a 200-day moving average price of GBX 606.44.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.